MTHFR gene polymorphism, homocysteine and cardiovascular disease
Open Access
- 1 April 2001
- journal article
- review article
- Published by Cambridge University Press (CUP) in Public Health Nutrition
- Vol. 4 (2b) , 493-497
- https://doi.org/10.1079/phn2001159
Abstract
Homocysteine is an emerging new risk factor for cardiovascular disease. It is a thiol compound derived from methionine and involved in two main metabolic pathways: the cycle of activated methyl groups, requiring folate and vitamin B12 as cofactors, and the transsulfuration pathway to cystathionine and cysteine requiring vitamin B6 as cofactor. The homocysteine metabolism represents an interesting model of gene-environment interaction. Elevations in homocysteine may be caused by genetic defects in enzymes involved in its metabolism or by deficiencies in cofactor levels. A common polymorphism in the gene coding for the 5, 10-methylene tetrahydrofolate reductase (MTHFR) (C677T, Ala → Val) is associated with a decreased activity of the enzyme due to thermolability. In case of homozygosity for the Val allele, a relative deficiency in the remethylation process of homocysteine into methionine leads to a mild-to-moderate hyperhomocysteinemia, a condition recognized as an independent risk factor for atherosclerosis. The genetic influence of the MTHFR polymorphism on homocysteine levels is attenuated in females in premenopausal age and is not significant in subjects who exhibit serum levels of folate and/or vitamin B12 above the 50th percentile of distribution in the general population. The prevalence of the Val/Val genotype varies among different ethnic groups. It is very low in African populations, whereas in Europe and North America it ranges between 5% and 15%. In Italy an even higher prevalence has been reported in some regions. The question whether the MTHFR polymorphism might be per se an independent contributor to cardiovascular risk is debated. The interaction between this or other genetic factors and environmental/nutritional conditions (i.e. intake of vitamins such as folate) is a key determinant for homocysteine concentrations in healthy conditions as well as in some disease (i.e. in renal disorders). Another example of gene/environment interaction in the field of atherosclerosis is given by the apolipoprotein E polymorphism and its influence in response to diet. The presence of a high prevalence of risk-related allelic variants of such candidate genes within a certain population could serve to locally reinforce the recommendations concerning nutrient intake.Keywords
This publication has 17 references indexed in Scilit:
- Influence of 5,10-methylenetetrahydrofolate reductase gene polymorphism on plasma homocysteine concentration in patients with end-stage renal diseaseAmerican Journal of Kidney Diseases, 1999
- The Effect of Folic Acid Fortification on Plasma Folate and Total Homocysteine ConcentrationsNew England Journal of Medicine, 1999
- Heterogeneity in World Distribution of the Thermolabile C677T Mutation in 5,10-Methylenetetrahydrofolate ReductaseAmerican Journal of Human Genetics, 1998
- MTHFR association with arteriosclerotic vascular disease?Human Genetics, 1998
- Homocysteine and AtherothrombosisNew England Journal of Medicine, 1998
- C677T (thermolabile alanine/valine) polymorphism in methylenetetrahydrofolate reductase (MTHFR): its frequency and impact on plasma homocysteine concentration in different European populationsAtherosclerosis, 1998
- Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patientsAtherosclerosis, 1996
- Relation Between Folate Status, a Common Mutation in Methylenetetrahydrofolate Reductase, and Plasma Homocysteine ConcentrationsCirculation, 1996
- A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductaseNature Genetics, 1995
- Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype.Journal of Clinical Investigation, 1987